作者
Lucy E Farrimond, Emmert Roberts, Rupert McShane
发表日期
2012/1/1
来源
BMJ open
卷号
2
期号
3
页码范围
e000917
出版商
British Medical Journal Publishing Group
简介
Background
Memantine is licensed for moderate-to-severe Alzheimer's disease (AD). National Institute for Clinical Excellence (NICE) guidance does not recommend the use of memantine in combination with cholinesterase inhibitors (acetylcholinesterase inhibitor (AChEI)). The underpinning meta-analysis was disputed by the manufacturer.
Objectives
To compare the efficacy of AChEI monotherapy with combination memantine and AChEI therapy in patients with moderate-to-severe AD and to examine the impact of including unpublished data on the results.
Design
Systematic review and meta-analysis of randomised controlled trials.
Data sources
The Cochrane Dementia Group trial register, ALOIS, searched for the last time on 3 May 2011.
Data synthesis
Data from four domains (clinical global, cognition, function, behaviour and mood) were pooled. Sensitivity analyses examined the impact on the NICE-commissioned …
学术搜索中的文章
LE Farrimond, E Roberts, R McShane - BMJ open, 2012